Fig. 1
From: Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
Generation of BYL719-resistant breast cancer cell lines. a Immunoblots of lysates from T47D and MCF7 cells treated for 1 hour with increasing concentrations of BYL719. Immunoblot quantification used ImageJ software (developed at the U. S. National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). b Schematic of the generation of BYL719-resistant breast cancer cell lines. Parental cells were treated chronically with respective IC90 (90 % inhibitory concentrations) of BYL719 for a period of 5–6 months. c Curves showing BYL719 dose-responses of parental and resistant lines after 3 days of treatment. Cell number was evaluated using the sulforhodamide B assay. GI50 (50 % growth inhibition) values were calculated using GraphPad Prism 6 software. Data are mean ± SEM (n >3). d Immunoblots of lysates from parental and resistant cells treated with respective IC90 (90 % inhibitory concentrations) of BYL719 as indicated. MCF7p MCF7-parental, MCF7r MCF7-resistant, SEM standard error of the mean, T47Dp T47D-parental, T47Dr T47D-resistant